New England Research & Management’s Colgate-Palmolive CL Stock Holding History

New England Research & Management’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$760K	Hold	8,288	–	–	0.3%	82
2026 Q1	$706K	Hold	8,288	–	–	0.3%	87
2025 Q4	$655K	Hold	8,288	–	–	0.29%	87
2025 Q3	$663K	Hold	8,288	–	–	0.3%	90
2025 Q2	$753K	Hold	8,288	–	–	0.36%	87
2025 Q1	$777K	Hold	8,288	–	–	0.39%	76
2024 Q4	$753K	Hold	8,288	–	–	0.38%	85
2024 Q3	$860K	Hold	8,288	–	–	0.4%	78
2024 Q2	$804K	Hold	8,288	–	–	0.39%	80
2024 Q1	$746K	Hold	8,288	–	–	0.37%	93
2023 Q4	$661K	Hold	8,288	–	–	0.35%	91
2023 Q3	$589K	Hold	8,288	–	–	0.34%	94
2023 Q2	$639K	Hold	8,288	–	–	0.37%	82
2023 Q1	$623K	Sell	8,288 -550	-6%	-$40.9K	0.37%	94
2022 Q4	$696K	Hold	8,838	–	–	0.4%	89
2022 Q3	$621K	Sell	8,838 -100	-1%	-$7.84K	0.39%	86
2022 Q2	$716K	Hold	8,938	–	–	0.42%	94
2022 Q1	$678K	Hold	8,938	–	–	0.35%	87
2021 Q4	$763K	Hold	8,938	–	–	0.37%	83
2021 Q3	$676K	Hold	8,938	–	–	0.35%	89
2021 Q2	$727K	Hold	8,938	–	–	0.38%	95
2021 Q1	$705K	Hold	8,938	–	–	0.39%	84
2020 Q4	$764K	Hold	8,938	–	–	0.47%	73
2020 Q3	$690K	Hold	8,938	–	–	0.5%	73
2020 Q2	$655K	Sell	8,938 -50	-0.6%	-$3.55K	0.47%	77
2020 Q1	$596K	Hold	8,988	–	–	0.51%	70
2019 Q4	$619K	Hold	8,988	–	–	0.41%	86
2019 Q3	$661K	Sell	8,988 -100	-1%	-$7.25K	0.48%	74
2019 Q2	$651K	Sell	9,088 -100	-1%	-$7.1K	0.44%	85
2019 Q1	$630K	Hold	9,188	–	–	0.43%	83
2018 Q4	$547K	Hold	9,188	–	–	0.43%	80
2018 Q3	$615K	Hold	9,188	–	–	0.4%	89
2018 Q2	$595K	Buy	9,188 +6,288	+217%	+$411K	0.39%	99
2018 Q1	$208K	Hold	2,900	–	–	0.14%	152
2017 Q4	$219K	Sell	2,900 -100	-3%	-$7.3K	0.16%	139
2017 Q3	$219K	Hold	3,000	–	–	0.16%	142
2017 Q2	$222K	Hold	3,000	–	–	0.16%	144
2017 Q1	$220K	Sell	3,000 -200	-6%	-$14K	0.17%	152
2016 Q4	$209K	Sell	3,200 -400	-11%	-$27.4K	0.16%	164
2016 Q3	$267K	Sell	3,600 -3,700	-51%	-$274K	0.22%	136
2016 Q2	$534K	Sell	7,300 -1,650	-18%	-$117K	0.46%	72
2016 Q1	$632K	Buy	8,950 +200	+2%	+$13.3K	0.54%	65
2015 Q4	$583K	Buy	8,750 +1,600	+22%	+$106K	0.5%	71
2015 Q3	$454K	Buy	+7,150	New	+$467K	0.43%	86

Other funds holding CL

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Sarasin & Partners London, United Kingdom $8.54B AUM 9.6% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAM

PineStone Asset Management Montreal, Quebec, Canada $16.2B AUM 25.74% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

JIC

Johnson Investment Counsel Cincinnati, Ohio $13.7B AUM 21.52% 1-Year Est. Return

Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return

New England Research & Management's CL Position: Q2 2026 in Review

New England Research & Management held its Colgate-Palmolive (CL) position steady in Q2 2026 at 8,288 shares worth $760K. The position accounts for 0.3% of the portfolio, ranked #82.

New England Research & Management first reported a position in CL in Q3 2015 and has held it in 44 quarters since. The position peaked at $860K in Q3 2024. 623 funds tracked by Wall St. Rank hold CL as of Q2 2026.

New England Research & Management held 8,288 shares of Colgate-Palmolive worth $760K as of Q2 2026.
New England Research & Management left its Colgate-Palmolive share count unchanged in Q2 2026.
Colgate-Palmolive made up 0.3% of New England Research & Management's portfolio in Q2 2026, its #82 holding.
New England Research & Management first reported a position in Colgate-Palmolive in Q3 2015 and has held it in 44 quarters since.
New England Research & Management's Colgate-Palmolive position peaked at $860K in Q3 2024.
623 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q2 2026.

Based on New England Research & Management's 13F filing for Q2 2026, filed 9 Jul 2026.